Shares of Ariad have more than doubled in price over the past year, climbing sharply since the start of 2012, amid projections that ponatinib, its treatment for chronic myeloid leukemia, or CML, eventually could generate annual sales of more than $1 billion.
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢